Deltex Medical specializes in haemodynamic monitoring and offers solutions to combat haemodynamic instability in surgery and critical care. The company's technology aims to reduce complications such as acute kidney injury and respiratory distress.

Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, Spain, Canada, and internationally. It offers esophageal Doppler Probes that is used to measure a patient's central vascular blood flow and fluid status to measure real time blood velocities within the descending aorta; Loops plots aortic blood flow velocity and aortic blood pressure monitoring throughout every heartbeat; High Definition Impedance Cardiography, a non-invasive cardiac function and fluid status monitoring system for awake patients; and PressureWave, a pulse pressure waveform analysis algorithm used during periods of instability or for periods when the ODM mode is unavailable. The company also provides Deltex Medical Esophageal Doppler Simulator that enables clinicians to practice probe insertion, focusing, and waveform interpretation outside of a patient setting. Its products are used in Covid-19 critical care; sepsis; major abdominal, laparoscopic, and spinal surgeries; cardiac, trauma, and transplant procedures; and post-operative acute kidney injury monitoring. Deltex Medical Group plc was incorporated in 2000 and is headquartered in Chichester, the United Kingdom.

DEMG

COM:DELTEXMEDICAL

Deltex Medical

Last Close

0.07

21/11 13:20

Market Cap

27.49K

Beta: -

Volume Today

85.40M

Avg: -

locale

market

industry

website

ipo date

peer of

Metrics